Castle Biosciences, Inc. (CSTL)
- Previous Close
19.61 - Open
19.61 - Bid 19.94 x 100
- Ask 20.14 x 100
- Day's Range
19.61 - 20.67 - 52 Week Range
9.26 - 26.70 - Volume
187,583 - Avg. Volume
235,982 - Market Cap (intraday)
553.397M - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
-- - EPS (TTM)
-2.14 - Earnings Date May 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.11
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
castlebiosciences.com610
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CSTL
Performance Overview: CSTL
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CSTL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CSTL
Valuation Measures
Market Cap
552.98M
Enterprise Value
325.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.44
Price/Book (mrq)
1.41
Enterprise Value/Revenue
1.48
Enterprise Value/EBITDA
-7.22
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.15%
Return on Assets (ttm)
-9.43%
Return on Equity (ttm)
-14.54%
Revenue (ttm)
219.79M
Net Income Avi to Common (ttm)
-57.47M
Diluted EPS (ttm)
-2.14
Balance Sheet and Cash Flow
Total Cash (mrq)
243.1M
Total Debt/Equity (mrq)
3.94%
Levered Free Cash Flow (ttm)
818.5k